Accessibility Menu
AbCellera Biologics logo

AbCellera Biologics

(NASDAQ) ABCL

Current Price$7.62
Market Cap$2.32B
Since IPO (2020)-87%
5 Year-63%
1 Year+118%
1 Month+18%

AbCellera Biologics Financials at a Glance

Market Cap

$2.32B

Revenue (TTM)

$79.21M

Net Income (TTM)

-$143.96M

EPS (TTM)

-$0.48

P/E Ratio

-15.85

Dividend

$0.00

Beta (Volatility)

1.43 (Average)

Price

$7.62

Volume

35,883.892

Open

$7.69

Previous Close

$7.60

Daily Range

$7.27 - $7.86

52-Week Range

$2.75 - $8.42

Estimated Earnings Date

Aug 6, 2026

ABCL: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AbCellera Biologics

Industry

Life Sciences Tools and Services

Employees

562

CEO

Carl Lars G. Hansen, PhD

Headquarters

Vancouver, BC V5Y 0A1, CA

ABCL Financials

Key Financial Metrics (TTM)

Gross Margin

79.07%

Operating Margin

-267.61%

Net Income Margin

-181.75%

Return on Equity

-14.86%

Return on Capital

-19.56%

Return on Assets

-11.01%

Earnings Yield

-6.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.32B

Shares Outstanding

305.38M

Volume

35.88K

Avg. Volume

7.57M

Financials (TTM)

Gross Profit

$62.63M

Operating Income

-$211.96M

EBITDA

-$157.61M

Operating Cash Flow

-$153.26M

Capital Expenditure

-$35.97M

Free Cash Flow

-$189.23M

Cash & ST Invst.

$504.73M

Total Debt

$140.18M

AbCellera Biologics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.32M

+96.3%

Gross Profit

-$340.00K

-108.0%

Gross Margin

-4.09%

N/A

Market Cap

$2.32B

N/A

Market Cap/Employee

$3.89M

N/A

Employees

596

N/A

Net Income

-$43.17M

+5.4%

EBITDA

-$40.88M

+21.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$504.73M

-16.6%

Total Debt

$140.18M

+106.6%

Accounts Receivable

$115.73M

-8.6%

Inventory

$7.86M

N/A

Long Term Debt

$134.31M

+112.5%

Short Term Debt

$5.87M

+26.6%

Return on Assets

-11.01%

N/A

Return on Invested Capital

-16.82%

N/A

Free Cash Flow

-$37.35M

-68.3%

Operating Cash Flow

-$33.52M

-190.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PHVSPharvaris N.V.
$33.95-1.82%
CLDXCelldex Therapeutics, Inc.
$36.78-1.16%
IMNMImmunome, Inc.
$21.49+1.42%
NUVBNuvation Bio Inc.
$5.42-4.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$197.73-0.01%
NUNu Holdings
$13.40+0.00%
AAPLApple
$294.34+0.02%
CRWVCoreWeave
$85.73-0.14%

Questions About ABCL

What is the current price of AbCellera Biologics?

AbCellera Biologics is trading at $7.60 per share.

What is the 52-week range for AbCellera Biologics?

Over the past 52 weeks, AbCellera Biologics has traded between $2.75 and $8.42.

How much debt does AbCellera Biologics have?

As of the most recent reporting period, AbCellera Biologics reported total debt of $140.18M.

How much cash does AbCellera Biologics have on hand?

AbCellera Biologics reported $102.06M in cash and cash equivalents in its most recent financial results.

What is AbCellera Biologics’s dividend yield?

AbCellera Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.